Make Informed Investment Decisions with Affordable Access to Experts
Another Look: Examining the market potential of DBV's Viaskin Patch and Aimmune’s AR-101 with an allergist at an academic institutionTicker(s): AIMT, DBVT
Name: Dr Melanie Makhija - MD
- Assistant Professor, Pediatrics at Northwestern; Clinical and research interests focus on food allergy including oral, sublingual and epicutaneous immunotherapy for food, eosinophilic esophagitis, asthma, and primary immunodeficiency.
- Treats approximately 500 patients with peanut allergy & 200 patients with cow’s milk allergy (CMPA).
- Primary and co-investigator on several multi-center national and international food allergy, immunology and asthma clinical trials.
Please describe your clinical background and how you currently manage your peanut allergy patients.Added By: c_admin
What % of your patients would you anticipate wanting to use AR101 if approved?Added By: c_admin
Can you give us your opinion as to how the safety vs benefit balance between the two drugs?
Is there still a need for a different treatment option or do these two potential entries to market cover most all patient cases you see?Added By: c_admin
How does the route of administration factor into treatment decision making? more specifically, for the pediatric audience?Added By: c_admin
I the Viaskin patch effective enough to get FDA approval?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.